Bilastine mesylate was jointly developed by Tanabe Seiyaku Co., Ltd. of Japan and Ube Industries Co., Ltd. of Japan. It received marketing approval from the Japanese PMDA on July 3, 2000, and from the U.S. FDA on September 8, 2009. Bilastine is an H1‑receptor antagonist with selective inhibitory activity at the histamine H1 receptor; it also suppresses eosinophil infiltration into inflammatory sites and inhibits the production of IL‑5 by activated eosinophils, thereby alleviating allergic inflammation. It is commonly used to treat allergic rhinitis, urticaria, eczema, and other conditions. Bilastine mesylate poorly crosses the blood–brain barrier, exhibits no sedative effects, and displays a dissociated anticholinergic–antihistaminic profile. Other adverse reactions are minimal, and it demonstrates excellent pharmacodynamic properties and clinical efficacy, with a potency superior to that of ketotifen, terfenadine, cetirizine, and epinastine.
Bilastine benzenesulfonate It was jointly developed by Tanabe Seiyaku Co., Ltd. of Japan and Ube Industries Co., Ltd. of Japan, received marketing approval from the Japanese PMDA on July 3, 2000, and was approved for marketing by the U.S. FDA on September 8, 2009. Betastine is an H1‑receptor antagonist belonging to the antihistamine class; it selectively inhibits histamine H1 receptors and also suppresses the migration of eosinophils to sites of inflammation, inhibiting the production of IL‑5 by activated eosinophils and thereby alleviating allergic inflammation. It is commonly used to treat allergic rhinitis, urticaria, eczema, and other conditions. Bilastine mesylate rarely penetrates the brain, exhibits no sedative effects, and demonstrates a dissociation between its anticholinergic and antihistaminic activities. It is associated with minimal other adverse reactions and possesses favorable pharmacodynamic properties and clinical efficacy, with a potency superior to that of ketotifen, terfenadine, cetirizine, and epinastine.

Figure | Chemical structure of betahistine besylate
According to data from MeneNet, sales of betastine tablets at the terminal level in China’s public medical institutions have grown rapidly, reaching RMB 44.95 million in 2018, with only the original research manufacturer, Tanabe Mitsubishi Pharma, holding a share. In 2019, generic versions of the drug were successfully approved for launch in China. Globally, betastine generated RMB 474 million in sales in 2018, and it holds promising prospects for clinical application. As industrialization deepens, the air pollution index has risen sharply, and the incidence of allergic inflammation has been steadily increasing. Clinical studies have demonstrated that betahistine mesylate exhibits rapid onset of action and a low incidence of adverse effects, such as somnolence.
Given the remarkable therapeutic efficacy and widespread clinical use of bilastine mesylate, its efficient synthesis has attracted considerable interest among pharmaceutical synthetic chemists. Numerous synthetic routes to bilastine mesylate have been reported, with the following four being the most prominent.
Process Route 1: Using inexpensive and readily available 2-pyridinecarbaldehyde and p-chlorobromobenzene as starting materials, the process involves a Grignard reaction, halogenation, nucleophilic substitution, hydrolysis, resolution, and further substitution; finally, the product is converted into its benzenesulfonate salt to yield optically pure benzenesulfonate of bilastine.

Figure | Process Route 1
Process Route 2: The process still uses 2-pyridinecarbaldehyde and p‑chlorobromobenzene as starting materials, with the initial steps identical to Route 1. Subsequently, optical‑pure benzenesulfonate of bilastine is obtained by first hydrolyzing the intermediate, followed by resolution, and finally forming a salt with benzenesulfonic acid.

Figure | Process Route 2
Process Route 3: Using 2-pyridinecarboxylic acid and chlorobenzene as starting materials, optically pure benzenesulfonate of betastine is obtained through a Friedel–Crafts reaction, chiral reduction catalyzed by a noble metal, etherification, hydrolysis, substitution, and finally salt formation with benzenesulfonic acid.

Figure | Process Route 3
Because the preceding synthetic routes involve salt formation and resolution, they are characterized by cumbersome operational procedures, low yields, and relatively high production costs. , Furthermore, the third process route involves precious-metal catalysts; the use of such catalysts drives up the synthesis cost, making these routes unsuitable for industrial-scale production.
We conducted high-throughput screening of the first-step process using Shangke Bio’s proprietary carbonyl reductase enzyme library, thereby completely avoiding the use of precious-metal catalysts. Process Route 4: Starting from 2-pyridinecarboxylic acid and chlorobenzene, the registered starting material is obtained via a Friedel–Crafts reaction. Subsequently, a carbonyl reductase (KRED) is employed to afford the key intermediate 01 with high selectivity and high conversion. This intermediate is then subjected to hydrolysis and substitution, followed by salt formation with benzenesulfonic acid, yielding optically pure betastine benzenesulfonate.

Figure | Process Route 4
Enzyme-catalyzed technology is one of the best solutions for achieving green chemistry, offering numerous advantages over conventional chemical synthesis: Enzyme catalysis avoids the use of toxic catalysts, enables reactions to proceed under mild conditions, generates fewer by‑products and minimizes waste, effectively shortens synthetic routes, delivers higher catalytic efficiency and stereoselectivity, and facilitates low‑cost, high‑quality production. As an essential component of green chemistry, biocatalytic technology has been widely adopted in the production of blockbuster drugs and key pharmaceutical intermediates, underscoring the industry’s future trajectory: integrating biocatalysis will increasingly become a standard choice in the synthetic processes of new drug development.